Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.51 |
| ▸ | CES1 | P23141 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11367507 | 0.86 | TSHR (0.59) | TSHRALDH1A1SMN1; SMN2LMNACES2 | |
| SCHEMBL11362791 | 0.84 | TSHR (0.61) | TSHRALDH1A1SMN1; SMN2LMNACES2 | |
| SCHEMBL2651119 | 0.84 | TSHR (0.61) | TSHRALDH1A1SMN1; SMN2LMNACES2 | |
| SCHEMBL296300 | 0.84 | TSHR (0.61) | TSHRALDH1A1SMN1; SMN2LMNACES2 | |
| SCHEMBL48947 | 0.83 | TSHR (0.59) | TSHRALDH1A1SMN1; SMN2LMNACES2 | |
| SCHEMBL1694325 | 0.83 | TSHR (0.59) | TSHRALDH1A1SMN1; SMN2LMNACES2 | |
| SCHEMBL7723429 | 0.83 | TSHR (0.59) | TSHRALDH1A1SMN1; SMN2LMNACES2 | |
| SCHEMBL2082576 | 0.83 | TSHR (0.59) | TSHRALDH1A1SMN1; SMN2LMNACES2 | |
| SCHEMBL641742 | 0.83 | TSHR (0.64) | TSHRALDH1A1SMN1; SMN2LMNACES2 | |
| Hydrochloric Acid SCHEMBL2532656 | 0.83 | TSHR (0.59) | TSHRALDH1A1SMN1; SMN2LMNACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902717-A2 | Vasopressin antagonist and oxytocin antagonist | Otsuka Pharmaceutical Company, Limited (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-0620003-B1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMA CO LTD (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-6972287-B1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | PFIZER INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | AUGELLI-SZAFRAN CORINNE ELIZAB (US) | 2004-11-04 | — | — | US | disclosed |
| EP-1225886-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-0765879-B1 | 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests | SANKYO CO (JP) | 2001-02-14 | — | — | EP | disclosed |
| WO-2000076489-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| US-5861429-A | MITICIDES AND ANTHELMINTICS | SANKYO COMPANY, LIMITED (JP) | 1999-01-19 | — | — | US | disclosed |
| US-5753644-A | Vasopressin antagonist and oxytocin antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5622947-A | VASODILATORS, HYPOTENSIVE AGENTS, DIURETICS, PLATELET AGGLUTINATION INHIBITORS; ALSO USED TO PREVENT PREMATURE BIRTH, TREAT DYSMENORRHEA | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-22 | — | — | US | disclosed |
| EP-0765879-A1 | 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests | SANKYO COMPANY LIMITED (JP) | 1997-04-02 | — | — | EP | disclosed |
| EP-0514667-B1 | Benzazepin derivatives as vasopressin antagonists | OTSUKA PHARMA CO LTD (JP) | 1995-08-09 | — | — | EP | disclosed |
| EP-0620003-A1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-5244898-A | Vasopressin antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0514667-A1 | Benzazepin derivatives as vasopressin antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-25 | — | — | EP | disclosed |
| US-4329454-A | Cephalosporin compounds | ELI LILLY AND COMPANY (US) | 1982-05-11 | — | — | US | disclosed |
| US-4133808-A | 4-(Formylthio)azetidinones and ozonization process therefor | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4048157-A | 4(Formylthio)-azetidin-2-ones and ozonization process therefor | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | APP, PSEN1, BACE1 | TSHR 4702/4885ALDH1A1 2945/4885SMN1; SMN2 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.